Investigational drug · Phase 3
TARA-002
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "TARA-002"
First trial start
2023
Sep 15, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TARA-002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bladder (Urothelial, Transitional Cell) Cancer
- Non-Muscle Invasive Bladder Carcinoma
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Non-muscle Invasive Bladder Cancer
- Lymphatic Malformation
Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "TARA-002" as an intervention, largest first.
- Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder CancerPivotal-lookingRecruiting
Protara TherapeuticsIndustry
NCT07480356 · 284 participants (planned) · Start May 29, 2026 · Primary completion Apr 2028
Drug: TARA-002; Investigator's Choice of Intravesical Chemotherapy · For: Bladder (Urothelial, Transitional Cell) Cancer; Non-Muscle Invasive Bladder Carcinoma; Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Sites: Queen Creek, Arizona; Little Rock, Arkansas; Bakersfield, California · 11 sites in all
Protara TherapeuticsIndustry
NCT05951179 · 131 participants (planned) · Start Sep 15, 2023 · Primary completion Oct 2031
Drug: TARA-002 · For: Non-muscle Invasive Bladder Cancer
Sites: Homewood, Alabama; Phoenix, Arizona; Queen Creek, Arizona · 78 sites in all
Protara TherapeuticsIndustry
NCT05871970 · 38 participants (planned) · Start Oct 18, 2023 · Primary completion Dec 2026
Drug: TARA-002 · For: Lymphatic Malformation
Sites: Birmingham, Alabama; Little Rock, Arkansas; Aurora, Colorado · 11 sites in all
Protara TherapeuticsIndustry
NCT05085977 · 12 participants · Start Mar 10, 2022 · Primary completion Sep 3, 2024
Drug: TARA-002 · For: Non-muscle Invasive Bladder Cancer
Sites: Los Angeles, California; Jacksonville, Florida; New Orleans, Louisiana · 14 sites in all
Protara TherapeuticsIndustry
NCT05085990 · 10 participants · Start May 8, 2023 · Primary completion Sep 12, 2024
Drug: TARA-002 · For: Non-muscle Invasive Bladder Cancer
Sites: Los Angeles, California; Jacksonville, Florida; New Orleans, Louisiana · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Bladder (Urothelial, Transitional Cell) Cancer
- sustained-release gemcitabine-docetaxelNDV-01Phase 31 trial
Relmada Therapeutics, Inc. · Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.